应用远红外线(FIR)治疗乳腺癌相关的淋巴水肿的肿瘤安全性研究

Safety study of far infrared ray(FIR)therapy for the treatment of breast cancer related lymphedema

目的探讨应用远红外线(FIR)治疗乳腺癌相关的淋巴水肿的肿瘤安全性。方法选取乳腺癌切除术后5年以上,且伴有1年以上上肢淋巴水肿的患者,分为FIR组和对照组,分别采用FIR治疗和绷带加压保守治疗。观察指标包括肿瘤标志物(CA153、CA125)、相关结构的超声检查,并对治疗后1年的不良反应进行监测。通过体外试验观察FIR对人乳腺癌细胞系(MCF7、MDA-MB-231)和人皮肤成纤维细胞的影响,分析比较乳腺癌细胞系和人真皮成纤维细胞系的活力、增殖、细胞周期和凋亡情况。结果两组患者治疗1年后,肿瘤标志物(CA153、CA125)浓度均未升高,且数据无统计学差异(P>0.05)。两组均未发现淋巴结肿大或新增大的淋巴肿瘤,无不良反应产生。体外试验表明,FIR辐射对成纤维细胞及MCF-7和MDA-MB-231的活力、增殖、细胞周期、凋亡均没有影响。结论用FIR治疗乳腺癌术后5年的上肢淋巴水肿是安全的。

Objective To investigate the safety of far infrared ray(FIR)treatment for postmastectomy lymphedema.Methods Patients who underwent mastectomy more than 5 years ago and complicated by upper extremity lymphedema for more than 1 year were included.The enrolled patients were divided into FIR group and control group,and treated with FIR and conservative treatment using bandage compression,respectively.Outcome measures included tumor markers(CA153,CA125),ultrasonography of relevant structures and monitoring for adverse reactions 1 year after treatment.For the in vitro part of the study,the effects of FIR on human breast adenocarcinoma cell lines(MCF7,MDA-MB231)and human dermal fibroblasts were considered.The viability,proliferation,cell cycle and apoptotic statistics of the human breast adenocarcinoma cell lines and human dermal fibroblasts were analyzed and compared.Results After FIR treatment for 1 year,the concentrations of tumor markers(CA153,CA125)in the FIR group and the control group were not elevated.There was no statistically significant difference between FIR and control group(P>0.05).Furthermore,no lymphadenectasis or newly enlarged lymph nodes were found in the two groups and no adverse events occurred.The in vitro experiment indicated that FIR radiation had no effect on the viability,proliferation,cell cycle and apoptosis of fibroblasts,MCF-7 and MDA-MB-231 cells.Conclusion FIR is safe for the treatment of breast cancer related lymphedema 5 years after mastectomy.